Cerebrolysin

Mechanism

Cerebrolysin is not a single peptide but a complex preparation. It is produced by enzymatic breakdown of porcine brain proteins, yielding a mixture of:

• Low-molecular-weight peptides (<10 kDa)
• Free amino acids
• Small biologically-active fragments

The exact composition varies by batch, which is part of why the regulatory status is complicated outside its approving markets. Quality control is conducted on biological activity rather than precise composition.

The proposed mechanisms (multiple, none definitively proven dominant):

• Neurotrophic activity — components mimic endogenous nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and other neurotrophic signals
• Anti-apoptotic effects in neurons under ischemic stress
• Synaptic plasticity modulation
• Anti-inflammatory effects in central nervous system

The breadth of proposed mechanisms reflects the complex composition. The downside of complexity is that no single mechanism can be definitively credited; the upside is that the drug has been used clinically for decades without a clear single-target failure point.

Standard administration is intravenous infusion at clinical doses (10–50 mL diluted in saline). Some intramuscular protocols exist for outpatient use.

What the evidence shows

Acute ischemic stroke (the primary indication):

• CASTA trial (Heiss et al, Stroke 2012): RCT of cerebrolysin in acute stroke, primary endpoint not met but secondary endpoints showed signal
• Bornstein et al meta-analysis (Acta Neurol Scand 2018): Multiple-trial meta-analysis showing modest benefit on neurological outcome scales
• Cochrane review (Ziganshina et al, 2020): “Cerebrolysin probably has little or no beneficial effect” for stroke recovery, but with moderate-quality evidence and confidence intervals that include benefit. The wording is conservative but the data is closer to “modest benefit” than “no effect.”

Vascular dementia:

• Multiple smaller trials showing improvements in cognitive scales (ADAS-cog+, MMSE) with cerebrolysin versus placebo
• Generally modest effect sizes; consistent direction

Traumatic brain injury:

• Smaller body of evidence, often in trauma-care contexts where blinded RCTs are difficult
• CAPTAIN trials (severe TBI) showed signal but were not large

Off-label cognitive enhancement / longevity:

• No published RCT evidence in healthy adults
• Anecdotal and biohacker-community-level reports of subjective effects
• The off-label use is the speculative end of the use spectrum

Why this is Promising and not Established:

The condition is right (stroke, dementia — clinically meaningful targets), the evidence base is real (multi-decade clinical use, multiple meta-analyses), but the effect sizes are modest and the high-quality trials have been mixed. Cochrane’s “probably little or no effect” language is conservative and likely understates the benefit, but it accurately reflects that the trial-quality picture is mixed.

Dosing literature

Approved dosing for acute ischemic stroke:

• 30 mL daily intravenous infusion for 10–20 days, often repeated in 2–3 month courses

Approved dosing for vascular dementia:

• 10–30 mL daily IV or IM, typically in 4-week courses repeated 2–3 times yearly

For off-label use:

Various protocols exist; none are based on RCT evidence in non-clinical-indication populations.

Risks and adverse events

Common (label and clinical experience):

• Mild infusion-site reactions
• Sweating during infusion (especially with rapid administration)
• Headache
• Transient feeling of warmth
• Nausea

Less common but reported:

• Hypersensitivity reactions (the porcine origin is a real allergenic concern)
• Confusion or agitation in some elderly patients
• Theoretical seizure threshold lowering (controversial; rare in practice)

Important contraindication:

The porcine origin makes this unsuitable for patients with religious or dietary restrictions on porcine products. This is not a small consideration in some patient populations.

Long-term safety:

The multi-decade clinical use in approving markets provides substantial post-marketing safety data. There are no major long-term safety signals. The clinical use pattern (intermittent courses rather than chronic continuous dosing) limits cumulative exposure.

Regulatory status

The geographic distribution of approval is unusual: significant clinical use in Europe, Russia, and Asia; complete absence from US clinical practice. This is a regulatory-pathway story rather than an evidence story.

Where to get it

For approved indications in approving markets: through clinicians (typically neurology) and hospital infusion centers.

In the US, cerebrolysin is not legally available through standard pharmaceutical distribution. Some patients access it through medical tourism or via specialty importation under personal-use exceptions. We do not endorse importation routes; the regulatory status is what it is.

We have no fulfillment partner for cerebrolysin and would not develop one — the IV/IM administration requirement makes it fundamentally a clinical-care product, not a direct-to-consumer one.

(See How we make money.)

References (selected)

1. Ziganshina LE, Abakumova T, Hoyle CHV. Cerebrolysin for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2020. PubMed
2. Bornstein NM et al. Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials. Acta Neurol Scand 2018.
3. Heiss WD et al. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke 2012 (CASTA).
4. Guekht A et al. Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial. J Neurol Sci 2011.
5. EVER Pharma product information — current revisions in approving markets.